3 Neil Woodford High-Yield Shares: GlaxoSmithKline plc, Centrica PLC and SSE PLC

GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) and SSE PLC (LON:SSE) are three of the master investor’s high-income picks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

gskRenowned fund manager Neil Woodford has been thrashing the market for a quarter of a century. Woodford is a very selective stockpicker. Fewer than 1 in 10 of the UK’s top 350 companies earn a place in his funds.

Hence, I always keep an eye on his holdings for promising investment ideas.

The following three FTSE 100 firms all currently offer prospective dividend yields of above 5.5%, compared with the FTSE 100 average of 3.3%:

  Recent share price Forecast yield
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) 1,417p 5.6%
Centrica (LSE: CNA) (NASDAQOTH: CPYYY) 307p 5.7%
SSE (LSE: SSE) 1,438 6.2%

GlaxoSmithKline

GSK’s shares are trading close to a 52-week low. Allegations of bribery in China, which have hurt sentiment, were already in the public domain when Woodford loaded up on GSK stock for his new fund towards the end of June.

However, the UK’s top pharma company has since released disappointing half-year results, with competition from generic drugs, some supply-chain problems and adverse currency movements all playing a part. Core earnings are now expected to be flat for the full year (at constant exchange rates).

Nevertheless, management said “we remain confident in GSK’s medium and long-term growth prospects”. The Board lifted the Q2 dividend (the ex-dividend date is 6 August) by 6%, and analysts’ full-year expectations give a prospective yield of 5.6%.

Centrica

Just as GSK’s China troubles didn’t stop Woodford from investing in the pharma firm, so the political and regulatory headwinds currently buffeting the UK’s energy utilities didn’t stop him backing Centrica, the owner of British Gas. As with GSK, Centrica’s shares are currently trading close to a 52-week low.

Also like GSK, Centrica has recently released disappointing first-half results. Abnormal weather conditions played a big part, and management said full-year earnings will be lower than last year.

However, the company expects a return to growth in 2015 and the Board reaffirmed its “commitment to real dividend growth”. The half-year payout was lifted 4% (ex-dividend date of 24 September), and analysts’ full-year forecasts give a prospective yield of 5.7%.

SSE

SSE faces the same challenging political and regulatory environment as Centrica. But again, Woodford has backed the previously named Scottish & Southern Energy for his new fund.

SSE told shareholders at its AGM last month that despite tough energy market conditions, “we are on course to give shareholders a return on their investment through a dividend increase that at least keeps pace with inflation”.

Analysts are forecasting a rise of 3% or so on last year’s payout, which gives a prospective top-of-the-tree yield of 6.2%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Exterior of BT head office - One Braham, London
Investing Articles

Near a 5-year high, is there still value in the BT share price?

With the BT share price near a five-year high, Mark Hartley analyses if there’s still value left for investors chasing…

Read more »

Group of friends meet up in a pub
Investing Articles

Here’s a surprising winner after the UK stock market reacts to the latest US tariffs — Diageo

Our writer was pleasantly surprised to see Diageo shares rise after US trade tariff news hit the UK stock market.…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Down from its all-time high, is the Rolls-Royce share price heading for a fall?

I keep thinking the Rolls-Royce share price could be set for a fall, and I keep being wrong. What about…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

The Jet2 share price nosedives despite record-breaking 2025 results

Investors sent the Jet2 share price lower in early trading today (9 July) as they reacted negatively to the leisure…

Read more »

British Pennies on a Pound Note
Investing Articles

At 36p, this penny stock could be worth considering

Edward Sheldon just scanned the UK market for penny stocks that are currently in strong upward trends. And this one…

Read more »

piggy bank, searching with binoculars
Investing Articles

Down 10% from May, is it time for me to buy more of this high-yielding FTSE heavyweight?

This FTSE 100 giant is forecast to have a 6.3% dividend yield by 2027, and looks substantially undervalued to me,…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Down 37% but with 47% forecast earnings growth and $1bn buyback announced, does Glencore’s share price look cheap to me?

Glencore’s share price has dropped over the year on concerns about China’s economic growth and US tariffs, but its earnings…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Up 10% in a month! What on earth’s going on with the Vodafone share price?

Our writer’s trying to find an explanation for the recent strong performance in the Vodafone share price. But it isn't…

Read more »